T cell-depleted nonmyeloablative stem cell transplantation: what is the optimum balance between the intensity of host conditioning and the degree of T cell depletion of the graft?
/kg CD3 + cells) without any further conditioning and has durable engraftment and is well with limited chronic GVHD. Patient 2 experienced secondary graft failure while still on low-dose steroids for grade 2 acute GVHD. She was conditioned with anti-thymocyte globulin (ATG) for 3 days followed by an unmanipulated graft (6 × 10 6 /kg CD34 + and 165 × 10 6 /kg CD3 + cells) and has durable engraftment. Both these patients were transplanted with active disease and are currently full donor chimeras with resolution of the original disease.
In view of the secondary graft failure in the first two patients without autologous reconstitution, a protocol modification was carried out with reduction in the dose of melphalan to 110 mg/m 2 and the amount of Campath-1H added to the apheresis product was reduced to 10 mg. The next two patients (Patients 3 and 4) had a durable engraftment without any GVHD, although Patient 4, who was transplanted for refractory NHL, succumbed to progressive disease. None had any evidence of cytomegalovirus (CMV) reactivation.
Based on these observations, we would like to emphasise two points. Firstly the intensity of host immunosuppression probably needs to match the degree of T cell depletion to facilitate durable engraftment. The use of ATG combined with early T cell add-back probably contributed to the low incidence of graft-failure experienced by Craddock et al 5 using similar doses of fludarabine and melphalan. Secondly, melphalan at a dose of 140 mg/m 2 in this setting is not innocuous and may result in the failure of autologous reconstitution. This was demonstrated in two of our patients as well as the patient reported by Craddock et al who had a graft failure. Although the use of Campath-1H in vivo appears to be a pragmatic approach at present in terms of both engraftment and GVHD, our protocol with reduced dose of melphalan and Campath 'in the bag' might be an effective alternative without the problems of additional immunosuppression. However, this needs to be explored in a larger cohort of patients. Thus, the ideal conditioning regimen for nonmyeloablative conditioning remains uncertain, and is likely to be different for T cell-replete and T cell-depleted grafts. 
